Astex Therapeutics Ltd announced that Astex and Janssen Pharmaceutica have entered into a research alliance focused on the research, development and commercialisation of novel drugs for the treatment of cancer.
The new agreement grants Janssen Pharmaceutica a worldwide exclusive license to compounds arising from Astex's novel FGFR inhibitor programme, and the parties are also to establish a new drug discovery alliance focused on the identification of novel inhibitors against a further two cancer drug targets.
The details can be read here.
No comments:
Post a Comment